The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
The adoption of AI/ML in life science R&D is hindered by the lack of high-quality, well-structured data and metadata, a challenge exacerbated by a proliferation of proprietary instrument data formats, siloed lab software applications, and the absence of wet lab-friendly data automation platforms. While some workflow-specific solutions exist, they are… Read More
A complex problem that took scientists a decade to explain was solved in just two days by a new artificial intelligence (AI) tool, the BBC has reported. Professor José Penadés and his team at from the Imperial College London Department of Infectious Disease had spent 10 years… Read More
Oxford Drug Design has been awarded £1 ($1.2) million in funding to progress its uUTI (uncomplicated urinary tract infection) antibacterial programme from PACE (Pathways to Antimicrobial Clinical Efficacy). In the UK, there were over 1.8 million hospital admissions involving UTIs between 2018-19 and 2022-23, with the condition… Read More
This is the latest episode of the free DDW narrated podcast, titled “The continued evidence of AI’s drug discovery value”, which covers two articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “How generative AI could improve drug discovery” and “Can… Read More
The Chan Zuckerberg Initiative (CZI) has launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology. To achieve this, CZI will collaborate with partners 10x Genomics, Ultima Genomics, and a group of… Read More
A study co-led by University of Toronto (U of T) researchers and Insilico Medicine has demonstrated the potential of quantum computing and artificial intelligence (AI) to transform the drug discovery pipeline. “It’s an exciting time to be working at the interface of chemistry, quantum computing and AI. Read More
‘The digital lab’ can mean different things to different people, but the term broadly covers three types of laboratory systems: data management, automation and robotics, and artificial intelligence (AI) and machine learning (ML). Labs are looking to the potential cost and time savings these technologies can bring in an increasingly… Read More
Standardisation is critical to extracting the full potential of analytical data – in facilitating data-driven science and AI/ML-powered innovation. A new whitepaper entitled ‘Standardization of Analytical Data: Best Practices‘ is now available to download for free. The whitepaper will help you: Review currently available standard formats Understand the pros… Read More
Standardisation is critical to extracting the full potential of analytical data – in facilitating data-driven science and AI/ML-powered innovation. This whitepaper will help you: Review currently available standard formats Understand the pros and cons of open and proprietary formats Ensure data is adequately prepared for scientists and AI/ML applications… Read More
Pharma R&D is transitioning toward an AI/data driven model of drug discovery, and great progress has been made in the last 20 years. To fully exploit the potential of this technology we must think holistically about how it is integrated into R&D. Fit-for-purpose data is essential, as are models that… Read More
It can take years, and cost billions, to get new drugs approved for clinical use, but technological advances are transforming drug discovery and development. The growing shift towards artificial intelligence (AI), including generative and predictive AI, can reduce the amount of time and money it takes to develop new… Read More
1 Servier and Google Cloud Servier and Google Cloud have announced an expanded five-year partnership focused on using AI and generative AI (gen AI) to accelerate the research and development (R&D) of innovative therapeutic solutions for patients. According to Servier, by analysing large amounts of medical data… Read More
David Gosalvez, Head of Product Strategy and Zev Wisotsky, Senior Principle Marketing Manager for Biologics at Revvity Signals, highlight how three powerful AI and ML capabilities are driving lab innovation: enhancing data accessibility, enabling intelligent chemical reaction recommendations, and automating complex cellular imaging. Enhancing data accessibility with generative AI A… Read More
This eBook, sponsored by Revvity, examines the increasing role of digital tools in drug discovery and how these innovations could impact the development of therapeutics in the future. Download this exclusive eBook to learn more about: How digital innovation is helping drugs and therapeutics to get to market faster The… Read More
